Welcome to the Somatuline® Depot
Acromegaly Answers Webinar Series
What you need to know about acromegaly,
its impact, and available treatment options
Somatuline® Depot is sponsoring four seminars online, at no cost to registrants. Valuable information will be presented by expert healthcare practitioners from across the nation, and will help you:
- Understand your diagnosis of acromegaly
- Learn about recent treatment advancements
- Discover how to plan your future while
managing the condition
- Get answers to your questions online, in real-time
To participate in all four Somatuline® Depot Webinars, please register by clicking the "Register Now" button to the right.
If you know others who may benefit from the Webinars, please tell them to register or send them an invitation with our Invite A Friend feature.
SOMATULINE® DEPOT Acromegaly Answers WEBINAR SERIES SCHEDULE*
Acromegaly: Understanding its Physical
and Emotional Impact
View Archived Webinar
Date: June 2, 2009
Time: 9PM ET/6PM PT
People with acromegaly may experience troubling symptoms. Learn all you can about the condition, including its causes, complications, physical and emotional impact,
and acromegaly treatment options. Remember, some changes that come with acromegaly can be alleviated or reversed if proper treatment is
provided.1, 2, 3
Presented by:
John D. Carmichael, MD
Karen Sadler, RN, BSN
The Pituitary Center, Cedars Sinai Medical Center
Acromegaly: Getting the Facts on Reimbursement and Dispelling the Myths
View Archived Webinar
Date: August 24, 2009
Time: 9PM ET/6PM PT
When it comes to acromegaly, there are misconceptions about how much it costs to treat it, how to calculate costs, how to understand and evaluate insurance coverage, and more. You will find some of the answers in this presentation and learn about Patient Access, Care, and Education (PACE™), a resource provided by the makers of Somatuline® Depot. Remember, treatment for acromegaly is widely covered by specialty and retail pharmacies.
Presented by:
Caroline Howard, Regional Account Manager for Managed Care
Kimberly Shumake, Patient Care Liaison
Tercica, Inc., Brisbane, CA
Acromegaly: Optimizing Disease Management
View Archived Webinar
Date: September 29, 2009
Time: 9PM ET/6PM PT
It’s important to manage your acromegaly. With early detection and proper treatment, you may reduce or reverse its harmful effects and serious complications, including the risk of early death. Learn about managing acromegaly, working with your healthcare team to establish the best course of treatment, and your role in putting the plan into action. 1, 2, 3
Presented by:
Joseph Pinzone, MD, MBA
Kathleen Schweinsberg, RN
Ohio State University Comprehensive Cancer Center/James Cancer Hospital and Solove Research Institute
1. Melmed S. Medical progress:acromegaly. N Engl J Med. 2006;355:2558-2573.
2. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews. 2004;25:102-152.
3. AACE Acromegaly Guidelines Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly. Endocr Pract. 2004;10(3):213-225.
Important Indication and Safety Information
Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline® Depot (lanreotide) Injection may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.
Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline® Depot (lanreotide) Injection 60mg.
There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline® Depot (lanreotide) Injection should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.
Somatuline® Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.
Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline® Depot (lanreotide) Injection may reduce the intestinal absorption of co-administered drugs. Caution should be used.
The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.
Please see Full Prescribing Information for additional important information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
Privacy Policy | Terms & Conditions | SomatulineDepot.com